Population pharmacokinetics and exposure –response relationship of trastuzumab and bevacizumab in early-stage breast cancer

ConclusionTumour uptake as assessed by SUVmax influences the pharmacokinetics of bevacizumab and trastuzumab. In early-stage breast cancer, elimination half-lives of these therapeutic monoclonal antibodies may be shorter than those previously reported in more advanced disease.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research